Close Menu

NEW YORK (360Dx) – Phoenix Molecular Designs of Vancouver, Canada, said today that it is collaborating with Roche to develop a companion diagnostic for a kinase inhibitor developed for triple-negative breast cancer.

The assay, which primarily uses immunohistochemistry, according to PhoenixMD, identifies activation of the RSK2 kinase in tumors by measuring nuclear RSK2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.